A Phase 3 Trial of Inhaled Mosliciguat in PH-ILD (PHrontier)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 376 participants.
Also called NCT07816185
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 376 participants
- Sponsor
- Pulmovant, Inc.
- Registry
-
NCT07816185
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Recruiting
Technical summary
Registry record NCT07816185. Randomized; quadruple masking; primary purpose treatment. Start 2026-08-31 (actual); primary completion 2029-01-28 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Phase 3 Trial of Inhaled Mosliciguat in PH-ILD (PHrontier)
- Condition
- Pulmonary Hypertension
- Condition
- Interstitial Lung Disease
- Condition
- Vascular Diseases
- Condition
- Cardiovascular Diseases
- Condition
- Fibrosis
- Intervention (Drug)
- Mosliciguat
- Intervention (Drug)
- Placebo
- Intervention (Device)
- Dry Powder Inhaler
- Lead sponsor
- Pulmovant, Inc.
Record details
- Record id
cardio:ct-nct07816185- Content hash
748a2d4da7b92567964d24dbda16029a40f1579b4d5078a242304a8c7d8f8756